Skip to content
Sign in

TCRT · NASDAQ

Alaunos Therapeutics (TCRT) Stock Price & Fundamentals

$386.26+1.07%+$4.10End-of-day price as of Oct 9, 2026

Alaunos Therapeutics (TCRT) closed at $386.26 on Oct 9, 2026, up 1.07% from the previous close of $382.16.

Share price, past year

1Y −8.94%

52-week range $370.66 – $489.83. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$386.26
Sep 30, 2026$374.75
Aug 31, 2026$385.26
Jul 31, 2026$401.20
Jun 30, 2026$413.76
May 29, 2026$422.84
Apr 30, 2026$448.13
Mar 31, 2026$457.79
Feb 27, 2026$476.43
Jan 30, 2026$477.24
Dec 31, 2025$446.10
Nov 28, 2025$438.87
Oct 31, 2025$435.08

Key statistics

Market cap
$960.30M
P/E (TTM)
—
EPS (TTM)
−$1.90
Revenue (TTM)
$3.00K
Net income (TTM)
−$4.01M
Shares outstanding
2.5M
Dividend yield
—
52-week range
$370.66 – $489.83

Alaunos Therapeutics's market cap is $960.30M, based on a share price of $386.26 and 2.5M shares outstanding as of Jun 30, 2026.

Financials

Alaunos Therapeutics reported revenue of $5.00K for fiscal 2025, down 50.00% from fiscal 2024.

Alaunos Therapeutics reported a net loss of $4.18M in fiscal 2025.

Annual revenue

FY12FY16FY17FY18FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Alaunos Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$5.00K−50.0%−$4.18M−83,520.0%−$2.20−$2.97M
FY2024ended Dec 31, 2024$10.00K+100.0%−$4.68M−46,790.0%−$2.92−$4.97M
FY2023ended Dec 31, 2023$5.00K−99.8%−$4.68M−93,580.0%−$21.97−$30.34M
FY2022ended Dec 31, 2022$2.92M+634.2%−$37.73M−1,291.2%−$2.61−$29.45M
FY2021ended Dec 31, 2021$398.00K—−$78.75M−19,786.7%−$0.37−$64.79M
FY2020ended Dec 31, 2020$0.00−100.0%−$79.98M—−$0.38−$66.79M
FY2018ended Dec 31, 2018$146.00K−99.1%−$53.12M−36,381.5%$0.96−$49.92M
FY2017ended Dec 31, 2017$15.90M+131.7%−$54.32M−341.7%−$0.53−$55.41M
FY2016ended Dec 31, 2016$6.86M+757.6%−$165.30M−2,409.2%−$1.32−$58.88M
FY2012ended Dec 31, 2012$800.00K—————
Alaunos Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$0.00−$952.00K−$0.41
Q1 FY2026ended Mar 31, 2026$0.00−$1.01M−$0.59
Q4 FY2025ended Dec 31, 2025$3.00K−$893.00K−$0.35
Q3 FY2025ended Sep 30, 2025$0.00−$1.16M−$0.55
Q2 FY2025ended Jun 30, 2025$0.00−$1.05M−$0.63
Q1 FY2025ended Mar 31, 2025$2.00K−$1.07M−$0.67
Q4 FY2024ended Dec 31, 2024$5.00K−$741.00K−$0.46
Q3 FY2024ended Sep 30, 2024$0.00−$1.13M−$0.70

Company profile

Name
Alaunos Therapeutics, Inc.
Ticker
TCRT
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
501 E Las Olas Blvd, Suite 300, Fort Lauderdale, FL 33301
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001107421

Recent SEC filings

Frequently asked questions

What is Alaunos Therapeutics's stock price?

Alaunos Therapeutics (TCRT) closed at $386.26 on Oct 9, 2026, up 1.07% from the previous close of $382.16.

What is Alaunos Therapeutics's market cap?

Alaunos Therapeutics's market cap is $960.30M, based on a share price of $386.26 and 2.5M shares outstanding as of Jun 30, 2026.

How much revenue does Alaunos Therapeutics make?

Alaunos Therapeutics reported revenue of $5.00K for fiscal 2025, down 50.00% from fiscal 2024.

Does Alaunos Therapeutics pay a dividend?

Alaunos Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Alaunos Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures